Acetazolamide for Treatment Resistant Schizophrenia (NCT04887792) | Clinical Trial Compass
RecruitingPhase 1/2
Acetazolamide for Treatment Resistant Schizophrenia
United States, India60 participantsStarted 2022-02-01
Plain-language summary
This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.
Who can participate
Age range18 Years – 55 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Written informed consent.
* Both genders, ages 18-55 years (older patients may not tolerate high ACZ dose).
* PANSS total score \> 60 and Score \> 4 on one or more items of the 'positive' syndrome items (P1-P7), following treatment at therapeutic doses for 6 weeks with different APDs on 2 occasions.
* Stable dose of antipsychotic drug (APD) for \> 1 month, continued throughout the study.
* Not participating in another randomized controlled clinical trial (RCT).
Exclusion Criteria:
* Substance abuse in the past month/dependence past 6 months with the exception of methadone prescribed for opiate withdrawal.
* History or current medical/neurological illnesses that may lead to unstable course, e.g., epilepsy.
* Pregnancy.
* Acetazolamide (ACZ) contraindications: hypersensitivity to ACZ; history of renal hyperchloremic acidosis; Addison's disease/adrenal failure; chronic closed angle-closure glaucoma.
* Current or prior treatment with ACZ or history of hypersensitivity to ACZ.
* Intellectual disability as defined in DSM 5.